Pathological response to neoadjuvant 5-FU, oxaliplatin, and docetaxel (FLOT) versus epirubicin, cisplatin, and 5-FU (ECF) in patients with locally advanced, resectable gastric/esophagogastric junction (EGJ) cancer: Data from the phase II part of the FLOT4 phase III study of the AIO

被引：1
|
作者：
Pauligk, Claudia
Tannapfel, Andrea
Meiler, Johannes
Luley, Kim Barbara
Kopp, Hans-Georg
Homann, Nils
Hofheinz, Ralf Dieter
Schmalenberg, Harald
Probst, Stephan
Haag, Georg Martin
Egger, Matthias
Behringer, Dirk M.
Stoehlmacher, Jan
Prasnikar, Nicole
Block, Andreas
Trojan, Jorg
Koenigsmann, Michael
Schmiegel, Wolff
Jaeger, Elke
Al-Batran, Salah-Eddin
机构：
[1] Univ Canc Ctr, Krankenhaus Nordwest, Frankfurt, Germany
[2] Ruhr Univ Bochum, Inst Pathol, Bochum, Germany
[3] Univ Hosp Essen, West German Canc Ctr, Dept Med Oncol, Essen, Germany
[4] UKSH Campus Luebeck, Lubeck, Germany
[5] Univ Hosp, Med Ctr 2, Tubingen, Germany
[6] Acad Teaching Hosp Wolfsburg, Dept Internal Med 2, Wolfsburg, Germany
[7] Univ Med Ctr Mannheim, Dept Hematol & Med Oncol, Mannheim, Germany
[8] Univ Klinikum Jena, Jena, Germany
[9] Klinikum Bielefeld, Bielefeld, Germany
[10] Univ Heidelberg Hosp, Natl Ctr Tumor Dis, Dept Med Oncol, Heidelberg, Germany
[11] Ortenau Klinikum Lahr, Lahr, Germany
[12] Augusta Kranken Anstalt, Bochum, Germany
[13] Univ Klinikum Carl Gustav Carus, Dresden, Germany
[14] Klinikum Ludwigsburg, Ludwigsburg, Germany
[15] Univ Hosp Hamburg Eppendorf, Hamburg, Germany
[16] Goethe Univ Frankfurt, D-60054 Frankfurt, Germany
[17] MediProjekt, Hannover, Germany
[18] Ruhr Univ Bochum, Knappschaftskrankenhaus, Dept Internal Med, Bochum, Germany
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2015年 / 33卷 / 15期
关键词：
D O I：
10.1200/jco.2015.33.15_suppl.4016
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
4016
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Pathological response to neoadjuvant 5-FU, oxaliplatin and docetaxel (FLOT) versus epirubicin, cisplatin and 5-FU (ECF) in patients with locally advanced, resectable gastric/esophagogastric junction (EGJ) cancer: Data from the phase II part of the FLOT4 phase III study of the AIO
    Pauligk, C.
    Tannapfel, A.
    Meiler, J.
    Luley, K. B.
    Kopp, H. G.
    Homann, N.
    Hofheinz, R. D.
    Schmalenberg, H.
    Probst, S.
    Haag, G. M.
    Egger, M.
    Behringer, D. M.
    Stoehlmacher, J.
    Prasnikar, N.
    Block, A.
    Trojan, J.
    Folprecht, G.
    Pohl, M.
    Schirmacher, P.
    Al-Batran, S. E.
    EUROPEAN JOURNAL OF CANCER, 2015, 51 : S728 - S728
  • [2] Interim safety analysis of a phase III trial with 5-FU, oxaliplatin, and docetaxel (FLOT) versus epirubicin, cisplatin, and 5-FU (ECF) in patients with locally advanced, resectable gastric/oesophagogastric junction (OGJ) cancer: The AIO-sto-0210 FLOT4 study
    Pauligk, Claudia
    Meiler, Johannes
    Hofheinz, Ralf Dieter
    Kopp, Hans-Georg
    Mayer, Frank
    Schmalenberg, Harald
    Luley, Kim
    Haag, Georg Martin
    Schmiegel, Wolff H.
    Homann, Nils
    Probst, Stephan
    Koenigsmann, Michael
    Prasnikar, Nicole
    Trojan, Jorg
    Egger, Matthias
    Mahlberg, Rolf
    Heike, Michael
    Tannapfel, Andrea
    Jaeger, Elke
    Al-Batran, Salah-Eddin
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [3] Interim safety results from a phase II/III trial with 5-FU, oxaliplatin, and docetaxel (FLOT) versus epirubicin, cisplatin, and 5-FU (ECF) in patients with locally advanced, resectable gastric/oesophagogastric junction (OGJ) cancer: A study of the AIO.
    Koock, Ulrike
    Pauligk, Claudia
    Luley, Kim Barbara
    Mayer, Frank
    Schulmann, Karsten
    Homann, Nils
    Schmalenberg, Harald
    Hozaeel, Wael
    Hofheinz, Ralf
    Probst, Stephan
    Mahlberg, Rolf
    Koenigsmann, Michael
    Haag, Georg Martin
    Meiler, Johannes
    Prasnikar, Nicole
    Behringer, Dirk M.
    Trojan, Jorg
    Egger, Matthias
    Jaeger, Elke
    Al-Batran, Salah-Eddin
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [4] Docetaxel and 5-FU continuous infusion (DF) versus epirubicin, cisplatin and 5-FU (ECF) for advanced gastric adenocarcinoma:: A randomised phase II study.
    Thuss-Patience, PC
    Kretzschmar, A
    Vielhaber, A
    Dörken, B
    Reichardt, P
    ANNALS OF ONCOLOGY, 2000, 11 : 67 - 67
  • [5] Quality of life in patients with advanced gastric cancer: a randomized trial comparing docetaxel, cisplatin, 5-FU (TCF) with epirubicin, cisplatin, 5-FU (ECF)
    Sanambar Sadighi
    Mohammad Ali Mohagheghi
    Ali Montazeri
    Zahra Sadighi
    BMC Cancer, 6
  • [6] Quality of life in patients with advanced gastric cancer: a randomized trial comparing docetaxel, cisplatin, 5-FU (TCF) with epirubicin, cisplatin, 5-FU (ECF)
    Sadighi, Sanambar
    Mohagheghi, Mohammad Ali
    Montazeri, Ali
    Sadighi, Zahra
    BMC CANCER, 2006, 6 (1)
  • [7] Feasibility of perioperative chemotherapy with infusional 5-FU, leucovorin, and oxaliplatin with (FLOT) or without (FLO) docetaxel in elderly patients with locally advanced esophagogastric cancer
    Lorenzen, S.
    Pauligk, C.
    Homann, N.
    Schmalenberg, H.
    Jaeger, E.
    Al-Batran, S-E
    BRITISH JOURNAL OF CANCER, 2013, 108 (03) : 519 - 526
  • [8] Feasibility of perioperative chemotherapy with infusional 5-FU, leucovorin, and oxaliplatin with (FLOT) or without (FLO) docetaxel in elderly patients with locally advanced esophagogastric cancer
    S Lorenzen
    C Pauligk
    N Homann
    H Schmalenberg
    E Jäger
    S-E Al-Batran
    British Journal of Cancer, 2013, 108 : 519 - 526
  • [9] A Phase II Study of Neoadjuvant Chemoradiotherapy with Docetaxel, Cisplatin and 5-FU Followed by Surgical Resection in the Treatment of Locally Advanced Esophagogastric Junction Cancer and Locally Advanced Esophageal Cancer
    Chen, Chien-Chih
    Yeh, Hui-Ling
    Chuang, Cheng-Yeh
    Hsu, Chung-Ping
    CLINICS AND PRACTICE, 2024, 14 (02) : 642 - 652
  • [10] Docetaxel, oxaliplatin, and fluorouracil/leucovorin (FLOT) versus epirubicin, cisplatin, and fluorouracil or capecitabine (ECF/ECX) as perioperative treatment of resectable gastric or gastroesophageal junction adenocarcinoma: The multicenter, randomized phase 3 FLOT4 trial (German Gastric Group at AIO)
    Salah-Eddin, Al-Batran
    Claudia, Pauligk
    Nils, Homann
    Harald, Schmalenberg
    Hans-Georg, Kopp
    Martin, Haag Georg
    Barbara, Luley Kim
    Wolff, Schmiegel H.
    Gunnar, Folprecht
    Stephan, Probst
    Nicole, Prasnikar
    Peter, Thuss-Patience C.
    Jorg, Trojan
    Oliver, Goetze Thorsten
    Johannes, Meiler
    Martin, Schuler H.
    Elke, Jaeger
    Ralf-Dieter, Hofheinz
    ANNALS OF ONCOLOGY, 2017, 28
12345